Board of Directors

Mark L. Baum is the founder, Chairman of the Board, and CEO of Harrow. For the 2014-2017 periods, Harrow (formerly Imprimis Pharmaceuticals) was named by Deloitte’s Technology Fast 500™ as one of the fastest growing companies in North America. Mr. Baum is also a founder of Eton Pharmaceuticals (NASDAQ: ETON) and Melt Pharmaceuticals, as well as a founder and board member of Surface Ophthalmics and Visionology. From 2014-2017, Mr. Baum was a senior advisor to VC-backed Curology.com. Prior to Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and patient/physician accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

R. Lawrence Van Horn has served as a director of the company since September 2020. Mr. Van Horn is an entrepreneur, board member, and leading expert and researcher on healthcare management and economics. A nontraditional academic, his activity spans business, health policy, and academia. His research has appeared in such leading journals as the Journal of Health Economics, Journal of Law and Economics, New England Journal of Medicine, Journal of Public Budgeting and Financial Management, and Harvard Business Review. He is the founder and CEO of Preverity, Inc. located in Nashville, Tennessee. Preverity is a healthcare analytic firm comprised of data scientists that has created the market-leading risk prediction platform for medical malpractice in the U.S., serving commercial malpractice insurers. Mr. Van Horn has extensive board experience on both public and private boards. Since its founding, he has been Governance Committee Chair and Compensation Committee Member for Community Health Care Realty Trust. He served as Compensation Committee Chair and Audit Committee Member for Quorum Health Corporation prior to it being taken private. He is the Board Chair for Savida Inc., a PE-backed MAT opioid treatment company with locations in Massachusetts, New Hampshire, Vermont, Delaware, and Virginia. He is a member of the CEO Council for Council Capital and advisory boards for Harpeth Capital and Council Capital. He is the Executive Director of Health Affairs and Founder and Director of the Center of Health Care Market Innovation at Vanderbilt University. He is also the Co-Director of Nashville Health Care Council Fellows Program. Professor Van Horn holds a Ph.D. from the University of Pennsylvania’s Wharton School and an M.B.A., a Master’s in Public Health and a B.A. from the University of Rochester.

Marty Makary, M.D., M.P.H., has served as a director of the company since March of 2022. Dr. Makary is a healthcare expert and is Chief of Islet Transplant Surgery at The Johns Hopkins Hospital, where he has been employed since 2002. Dr. Makary is a frequent public policy expert in the media and a leading voice for physicians, writing for The Wall Street Journal. He is the author of two New York Times bestselling books on healthcare and has published over 250 scientific peer-reviewed articles, including articles on organizational culture, surgical innovation, vulnerable populations, and the re-design of healthcare delivery. Dr. Makary has served in leadership at the World Health Organization and has been elected to the National Academy of Medicine. Dr. Makary has been a visiting professor at over 25 medical schools and is the recipient of the Nobility in Science Award from the National Pancreas Foundation. Dr. Makary speaks frequently on the future of healthcare and what it means for everyday Americans, business leaders, and healthcare professionals. His current research focuses on the appropriateness of medical care and the impact of the healthcare cost crisis on low-income populations. He has a B.S. degree from Bucknell University, an M.D. degree from Thomas Jefferson University, and a Master of Public Health (M.P.H.) degree, with a concentration in Health Policy, from Harvard University. Dr. Makary brings to the board extensive experience as a surgeon, corporate advisor, and policy thought leader.

Teresa F. Sparks has served as a director of the company since March of 2020. She recently served as CFO and Executive Vice President of Envision Healthcare, a leading provider of physician-led services and post-acute care services in addition to ambulatory surgery services. Previously, she was the interim CFO at Brookdale Senior Living, the CFO at Surgery Partners and its predecessor company, Symbion. Ms. Sparks began her career with Deloitte in Nashville, Tennessee, and healthcare was her primary area of focus. She brings extensive public corporate leadership in addition to private equity experience, having led two initial public offerings, a leveraged buy-out, and multiple mergers and acquisitions. Her public company experience incorporates strategy development, risk assessment, investor relations, and corporate governance. She has served as the chairperson for the Nashville Health Care Council’s Leadership Health Care (LHC) program and served on the Board of Trustees at Trevecca Nazarene University. Ms. Sparks completed the requirements to be a Certified Public Accountant (inactive) in the State of Tennessee and holds a Bachelor of Science in Business Administration and Accounting from Trevecca Nazarene University, graduating with Summa Cum Laude honors.

Perry J. Sternberg has served as a director of the company since March of 2022. He has served as President and Chief Executive Officer of Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, since 2019. Prior to joining Corium, he served from 2013 to 2019 as Executive Vice President and Head of U.S. Commercial for Shire Plc’s ophthalmology business unit as well as six other Shire business units, which, during his tenure, in the aggregate, generated more than $8 billion in annual revenues. Mr. Sternberg also served as Chief Commercial Officer and Global Head of Shire’s CNS Business. Mr. Sternberg previously served as Vice President and General Manager, U.S. and Canada Pharmaceuticals at Bausch + Lomb, as well as various leadership roles at Novartis Ophthalmics, Novartis Pharmaceuticals and Merck & Co., Inc. He received a B.S. degree in Animal Bioscience from Penn State University in 1990. Mr. Sternberg brings to the board over 25 years of experience in biotechnology and pharmaceuticals, having had direct responsibility for the launch and commercialization of more than 20 products across a wide range of therapeutic areas in diverse markets, including ophthalmic pharmaceuticals.